Trial Profile
Phase III Long-Term Study to Evaluate the Safety and Efficacy of CDB-2914 in Patients with Uterine Myoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Ulipristal (Primary)
- Indications Uterine leiomyoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors ASKA Pharmaceutical
- 01 Sep 2021 Status changed from active, no longer recruiting to completed.
- 01 Sep 2021 Results assessing the efficacy and safety of long-term intermittent administration of 10-mg ulipristal acetate (UPA) for symptomatic uterine fibroids in Japanese women published in the Journal of Obstetrics and Gynaecology Research
- 05 Dec 2018 Status changed from recruiting to active, no longer recruiting.